NEURONAL DEFENSE Trademark
Trademark Overview
On Wednesday, September 24, 2025, a trademark application was filed for NEURONAL DEFENSE with the United States Patent and Trademark Office. The USPTO has given the NEURONAL DEFENSE trademark a serial number of 99409682. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Tuesday, June 2, 2026. This trademark is owned by SoluPet Inc.. The NEURONAL DEFENSE trademark is filed in the Pharmaceutical Products category with the following description:
Natural dietary supplements comprising nanomicellar veterinary formulations of phenylpropyl silanetriol (PTS) carriers in combination with bioactive compounds for use in companion animals for supporting cognitive function, memory, learning ability and neural health in aging animals, mitigating oxidative stress and neuroinflammation associated with neurodegenerative processes, protecting and promoting survival of dopaminergic neurons in toxin-induced models of Parkinson-type and other neurodegenerations, providing prophylactic and therapeutic neuroprotection against environmental and endogenous neurotoxins, supporting nerve regeneration and repair following trauma, surgery or peripheral neuropathy, alleviating chemotherapy-induced neurotoxicity, including cisplatin-related peripheral neuropathy, supporting motor coordination, balance and reduction of gait abnormalities, modulating systemic inflammatory responses and supporting central cardiovascular regulatory mechanisms in endotoxemia ...
General Information
| Serial Number | 99409682 |
| Word Mark | NEURONAL DEFENSE |
| Filing Date | Wednesday, September 24, 2025 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Tuesday, June 2, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, June 23, 2026 |
Trademark Statements
| Goods and Services | Natural dietary supplements comprising nanomicellar veterinary formulations of phenylpropyl silanetriol (PTS) carriers in combination with bioactive compounds for use in companion animals for supporting cognitive function, memory, learning ability and neural health in aging animals, mitigating oxidative stress and neuroinflammation associated with neurodegenerative processes, protecting and promoting survival of dopaminergic neurons in toxin-induced models of Parkinson-type and other neurodegenerations, providing prophylactic and therapeutic neuroprotection against environmental and endogenous neurotoxins, supporting nerve regeneration and repair following trauma, surgery or peripheral neuropathy, alleviating chemotherapy-induced neurotoxicity, including cisplatin-related peripheral neuropathy, supporting motor coordination, balance and reduction of gait abnormalities, modulating systemic inflammatory responses and supporting central cardiovascular regulatory mechanisms in endotoxemia and SIRS models, maintaining cardiovascular health through antioxidant and anti-inflammatory actions, promoting ocular health by protecting retinal neurons from oxidative damage, providing adaptogenic support to reduce stress, anxiety and behavioral disorders, and supporting gut-brain axis homeostasis to indirectly influence mood and neural function; Pharmaceutical preparations comprising nanomicellar veterinary formulations of phenylpropyl silanetriol (PTS) carriers in combination with bioactive compounds for use in companion animals for supporting cognitive function, memory, learning ability and neural health in aging animals, mitigating oxidative stress and neuroinflammation associated with neurodegenerative processes, protecting and promoting survival of dopaminergic neurons in toxin-induced models of Parkinson-type and other neurodegenerations, providing prophylactic and therapeutic neuroprotection against environmental and endogenous neurotoxins, supporting nerve regeneration ; and repair following trauma, surgery or peripheral neuropathy, alleviating chemotherapy-induced neurotoxicity, including cisplatin-related peripheral neuropathy, supporting motor coordination, balance and reduction of gait abnormalities, modulating systemic inflammatory responses and supporting central cardiovascular regulatory mechanisms in endotoxemia and SIRS models, maintaining cardiovascular health through antioxidant and anti-inflammatory actions, promoting ocular health by protecting retinal neurons from oxidative damage, providing adaptogenic support to reduce stress, anxiety and behavioral disorders, and supporting gut-brain axis homeostasis to indirectly influence mood and neural function. |
| NOT AVAILABLE | "NEURONAL" |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, September 24, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | SoluPet Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Toronto M5X1A1
CA |
Trademark Events
| Event Date | Event Description |
| Wednesday, September 24, 2025 | NEW APPLICATION ENTERED |
| Wednesday, September 24, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, September 24, 2025 | APPLICATION FILING RECEIPT MAILED |
| Sunday, November 16, 2025 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Sunday, November 16, 2025 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Sunday, November 16, 2025 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Friday, January 30, 2026 | ASSIGNED TO EXAMINER |
| Thursday, February 19, 2026 | NON-FINAL ACTION WRITTEN |
| Thursday, February 19, 2026 | NON-FINAL ACTION E-MAILED |
| Thursday, February 19, 2026 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Saturday, May 16, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Saturday, May 16, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Saturday, May 16, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, May 26, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
